Microcap Ledger LeonaBio, Inc. $LONA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Bothell, WA
- Fiscal year end
- December 31
- Shares outstanding
- 9,421,663 [10-Q 2026-08-14]
What the company doesAI summary of filing
LeonaBio is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics for treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead program is lasofoxifene, a selective estrogen receptor modulator currently in a Phase 3 trial (ELAINE-3) for estrogen receptor-positive, HER2-negative metastatic breast cancer with ESR1 mutations, which the company in-licensed in December 2025. The company's second program is ATH-1105, a positive modulator of the neurotrophic HGF system that completed a Phase 1 trial and is being prepared for Phase 2 development in ALS. LeonaBio has not generated revenue from any marketed products, has not completed Phase 3 trials, and continues to incur operating losses. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$51.95M | −$37.86M | $32.32M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$106.00M | −$45.73M | $69.28M | [DEF 14A 2026-05-11] |
| FY ended Dec 2024 | — | −$97.00M | −$97.17M | $48.44M | [DEF 14A 2026-05-11] |
- Quarterly cash burn
- −$18.93M
- Cash runway Estimate
- ~5.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-07-29 | 38,439,375 | [10-Q/A 2024-08-09] |
| 2024-11-04 | 38,669,073 | [10-Q 2024-11-07] |
| 2025-02-24 | 39,042,445 | [10-K 2025-02-27] |
| 2025-05-06 | 39,042,445 | [10-Q 2025-05-09] |
| 2025-08-05 | 39,439,326 | [10-Q 2025-08-07] |
| 2025-11-05 | 3,943,887 | [10-Q 2025-11-06] |
| 2026-05-05 | 9,393,514 | [10-Q 2026-05-07] |
| 2026-08-04 | 9,421,663 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-01-20; declared effective 2026-04-01 [S-3 2026-01-20]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-04-16. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-04-16 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-16] |
| 2024-10-18 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-10-18] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-22 | 8-K | Other events |
| 2026-08-31 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-08-26 | 8-K | Other events |
| 2026-08-25 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-20 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-14 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-06-23 | 8-K | Shareholder vote results |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-11 | DEF 14A | Proxy statement |
| 2026-05-07 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | 10-Q | Quarterly report |
Alerts for $LONA
Email me when LeonaBio, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.